Review the Progression of Ovarian Clear Cell Carcinoma from the Perspective of Genomics and Epigenomics

Overview

Journal Front Genet

Date 2023 Mar 6

PMID 36873929

Authors

An Tong

Xiangjie Di

Xia Zhao

Xiao Liang

Affiliations

Soon will be listed here.

Abstract

Ovarian clear cell carcinoma (OCCC) is a rare subtype of epithelial ovarian cancer with unique molecular characteristics, specific biological and clinical behavior, poor prognosis and high resistance to chemotherapy. Pushed by the development of genome-wide technologies, our knowledge about the molecular features of OCCC has been considerably advanced. Numerous studies are emerging as groundbreaking, and many of them are promising treatment strategies. In this article, we reviewed studies about the genomics and epigenetics of OCCC, including gene mutation, copy number variations, DNA methylation and histone modifications.

Citing Articles

Molecular subtype of ovarian clear cell carcinoma: an analysis of 80 Chinese patients using the TCGA molecular classification of endometrial cancer.

Chen W, Yan L, Li Q, Zhou S, Hou T, Yang H BMC Cancer. 2025; 25(1):90.

PMID: 39815187 PMC: 11737267. DOI: 10.1186/s12885-024-13389-x.

Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M Int J Mol Sci. 2024; 25(21).

PMID: 39519256 PMC: 11546551. DOI: 10.3390/ijms252111703.

Spatial tumor immune microenvironment phenotypes in ovarian cancer.

Mateiou C, Lokhande L, Diep L, Knulst M, Carlsson E, Ek S NPJ Precis Oncol. 2024; 8(1):148.

PMID: 39026018 PMC: 11258306. DOI: 10.1038/s41698-024-00640-8.

: An Overview of Evidence, Demi-Decadal Trends, and Its Role in Adverse Pregnancy Outcomes and Various Gynecological Diseases, including Cancers.

Ghosh A, Jaaback K, Boulton A, Wong-Brown M, Raymond S, Dutta P Cells. 2024; 13(8.

PMID: 38667331 PMC: 11049087. DOI: 10.3390/cells13080717.

Application of interpretable machine learning algorithms to predict distant metastasis in ovarian clear cell carcinoma.

Guo Q, Xie F, Zhong F, Wen W, Zhang X, Yu X Cancer Med. 2024; 13(7):e7161.

PMID: 38613173 PMC: 11015070. DOI: 10.1002/cam4.7161.

References

Comoglio P, Boccaccio C . Scatter factors and invasive growth. Semin Cancer Biol. 2001; 11(2):153-65. DOI: 10.1006/scbi.2000.0366. View

Kimura A, Arakawa N, Kagawa H, Kimura Y, Hirano H . Phosphorylation of Ser1452 on BRG1 inhibits the function of the SWI/SNF complex in chromatin activation. J Proteomics. 2021; 247:104319. DOI: 10.1016/j.jprot.2021.104319. View

Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B . Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer. 2009; 125(10):2316-22. DOI: 10.1002/ijc.24587. View

Guan B, Suryo Rahmanto Y, Wu R, Wang Y, Wang Z, Wang T . Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst. 2014; 106(7). PMC: 4056776. DOI: 10.1093/jnci/dju146. View

Kuo K, Mao T, Chen X, Feng Y, Nakayama K, Wang Y . DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res. 2010; 16(7):1997-2008. PMC: 2848895. DOI: 10.1158/1078-0432.CCR-09-2105. View

Zannoni G, Improta G, Fraggetta F . PIK3CA in ovarian clear cell carcinoma. Hum Pathol. 2014; 45(12):2514. DOI: 10.1016/j.humpath.2014.07.023. View

Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A . Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res. 2004; 10(6):2000-6. DOI: 10.1158/1078-0432.ccr-0932-03. View

Wang H, Deng L, Cai M, Zhuang H, Zhu L, Hao Y . Annexin A4 fucosylation enhances its interaction with the NF-kB p50 and promotes tumor progression of ovarian clear cell carcinoma. Oncotarget. 2018; 8(64):108093-108107. PMC: 5746128. DOI: 10.18632/oncotarget.10226. View

Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, Takahashi R . Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther. 2013; 12(7):1367-77. PMC: 3852914. DOI: 10.1158/1535-7163.MCT-12-1185. View

10.

Caumanns J, Berns K, Wisman G, Fehrmann R, Tomar T, Klip H . Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clin Cancer Res. 2018; 24(16):3928-3940. PMC: 6098697. DOI: 10.1158/1078-0432.CCR-17-3060. View

11.

Oda K, Hamanishi J, Matsuo K, Hasegawa K . Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecol Oncol. 2018; 151(2):381-389. PMC: 7526052. DOI: 10.1016/j.ygyno.2018.09.001. View

12.

Yamaguchi K, Huang Z, Matsumura N, Mandai M, Okamoto T, Baba T . Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer. 2014; 135(3):585-97. PMC: 4522155. DOI: 10.1002/ijc.28701. View

13.

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

14.

Guan B, Wang T, Shih I . ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011; 71(21):6718-27. PMC: 3206175. DOI: 10.1158/0008-5472.CAN-11-1562. View

15.

Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R . Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. Mol Cancer Res. 2014; 13(4):795-806. PMC: 4398602. DOI: 10.1158/1541-7786.MCR-14-0314. View

16.

Kim S, Lee J, Lee M, Kim H, Chung H, Kim J . Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol Oncol. 2017; 148(2):375-382. DOI: 10.1016/j.ygyno.2017.12.005. View

17.

Diaz E, Walts A, Karlan B, Walsh C . Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013; 131(3):541-5. DOI: 10.1016/j.ygyno.2013.09.005. View

18.

Kato N, Sasou S, Motoyama T . Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2005; 19(1):83-9. DOI: 10.1038/modpathol.3800492. View

19.

Marchion D, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles X . A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013; 29(5):2011-8. PMC: 4536335. DOI: 10.3892/or.2013.2329. View

20.

Kuroda Y, Chiyoda T, Kawaida M, Nakamura K, Aimono E, Yoshimura T . ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer. Gynecol Oncol. 2021; 162(3):679-685. DOI: 10.1016/j.ygyno.2021.07.005. View